GPT Healthcare Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Healthcare Services | Market Cap: ₹1.3K Cr
The company expects a 15% year-on-year (Y-o-Y) growth driven by new hospitals and introduction of newer specialties in existing hospitals. GPT Healthcare expects a 15% year-on-year growth driven by new hospitals and introduction of newer specialties across existing hospitals.
From GPT Healthcare Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹151
Market Cap
₹1.3K Cr
P/E Ratio
27.1
How does GPT Healthcare Ltd rank in Healthcare Services?
Compare GPT Healthcare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
GPT Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹126 Cr, net profit ₹15 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company expects a 15% year-on-year (Y-o-Y) growth driven by new hospitals and introduction of newer specialties in existing hospitals.
- →Growth has been historically over 15% CAGR, though FY '25 saw largely flat volume growth due to external factors.
- →New hospital in Raipur expected to stabilize occupancies around 20% in the first year, breakeven at 35% occupancy within 24 months.
- →Jamshedpur hospital planned with 150 beds, expected commissioning by end of Q3 FY '27, contributing to future growth.
- →Focus on increasing Average Revenue Per Occupied Bed (ARPOB) by 8-12% annually across hospitals through specialty services and short-stay surgeries.
- →Occupancy rates targeted to improve in key hospitals for FY '26: Dum Dum ~72-73%, Salt Lake ~70%, Agartala ~55%, Howrah ~50%.
- →Oncology and other specialty expansions, including kidney transplant at Agartala, to enhance volumes.
📈 Profitability & Margins
- →GPT Healthcare expects a 15% year-on-year growth driven by new hospitals and introduction of newer specialties across existing hospitals.
- →EBITDA margin guidance for the coming year is forecasted between 22.5% to 23%, despite a 5-6% EBITDA impact due to losses from the new Raipur hospital.
- →The Raipur facility aims to break even within 24 months, targeting around 35% occupancy.
- →ARPOB (Average Revenue Per Occupied Bed) growth is projected at 7-15% across various hospitals, with specialty services like oncology and cardiology being key growth drivers.
- →Cost inflation is expected to be around 7-8%, with focused efforts on cost control to maintain profitability.
- →The company aims to strengthen operations, expand bed capacity to 1,000 beds over 2-3 years, and improve returns with an ROE of 23.5% reported in FY ’25.
🏗️ Capital Expenditure Plans
- →Commissioned a 158-bed facility at Pachpedi Naka in Raipur on May 2, 2025, under an asset-light rental model, marking significant capital investment.
- →Signed an MoU for a new 150-bed hospital in Jamshedpur with an estimated investment of approximately INR 65 crores; expected commissioning by end of Q3 FY '27.
- →Plans to scale up to a 1,000-bed hospital chain over the next 2 to 3 years through such expansions.
- →Raipur hospital project cost was approximately INR 55 crores.
- →Ranchi project is delayed awaiting developer clearances; no capex details given yet.
- →Focus on introducing newer specialties and expanding super-specialty treatments across existing and new hospitals to drive growth.
💰 Fundraising & Capital Structure
- →GPT Healthcare Limited has achieved a significant milestone by becoming a net debt-free company as of FY '25.
- →There has been a sharp decline in finance cost by 55% Y-o-Y, driven by a strategic reduction in debt.
- →No specific mentions or indications of any current or upcoming fundraisings through debt or equity were disclosed during the call.
- →The company is focusing on growth via operational expansion (e.g., Raipur hospital and planned Jamshedpur hospital) funded through internal or existing resources.
- →Overall, the management emphasized financial strength and balance sheet improvement, suggesting no immediate plans for fundraising through debt or equity.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What GPT Healthcare's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Suraksha Diagno. (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…
- Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Frequently Asked Questions
What were GPT Healthcare Ltd Q4 FY25 results?
The company expects a 15% year-on-year (Y-o-Y) growth driven by new hospitals and introduction of newer specialties in existing hospitals. GPT Healthcare expects a 15% year-on-year growth driven by new hospitals and introduction of newer specialties across existing hospitals.
What is GPT Healthcare Ltd share price analysis?
GPT Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 27.1 with a market cap of ₹1,281 Cr. Investors should review the full earnings analysis for detailed insights.
Is GPT Healthcare Ltd planning capital expenditure?
Commissioned a 158-bed facility at Pachpedi Naka in Raipur on May 2, 2025, under an asset-light rental model, marking significant capital investment.
Keep GPT Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.